Literature DB >> 26172131

Consensus conference on intrahepatic cholangiocarcinoma.

Ghassan K Abou-Alfa1,2, Jean-François Geschwind3, Michael Choti4, Michael I d'Angelica1,2.   

Abstract

Entities:  

Mesh：

Year:  2015        PMID： 26172131      PMCID： PMC4527849          DOI： 10.1111/hpb.12438

Source DB:  PubMed          Journal:  HPB (Oxford)        ISSN： 1365-182X            Impact factor:   3.647


× No keyword cloud information.
  9 in total

Review 1.  Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis.

Authors:  Anne M Horgan; Eitan Amir; Thomas Walter; Jennifer J Knox
Journal:  J Clin Oncol       Date:  2012-04-23       Impact factor: 44.544

2.  Intrahepatic cholangiocarcinoma: expert consensus statement.

Authors:  Sharon M Weber; Dario Ribero; Eileen M O'Reilly; Norihiro Kokudo; Masaru Miyazaki; Timothy M Pawlik
Journal:  HPB (Oxford)       Date:  2015-08       Impact factor: 3.647

3.  Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment.

Authors:  Mechteld C de Jong; Hari Nathan; Georgios C Sotiropoulos; Andreas Paul; Sorin Alexandrescu; Hugo Marques; Carlo Pulitano; Eduardo Barroso; Bryan M Clary; Luca Aldrighetti; Cristina R Ferrone; Andrew X Zhu; Todd W Bauer; Dustin M Walters; T Clark Gamblin; Kevin T Nguyen; Ryan Turley; Irinel Popescu; Catherine Hubert; Stephanie Meyer; Richard D Schulick; Michael A Choti; Jean-Francois Gigot; Gilles Mentha; Timothy M Pawlik
Journal:  J Clin Oncol       Date:  2011-07-05       Impact factor: 44.544

4.  Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.

Authors:  Juan Valle; Harpreet Wasan; Daniel H Palmer; David Cunningham; Alan Anthoney; Anthony Maraveyas; Srinivasan Madhusudan; Tim Iveson; Sharon Hughes; Stephen P Pereira; Michael Roughton; John Bridgewater
Journal:  N Engl J Med       Date:  2010-04-08       Impact factor: 91.245

5.  Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection.

Authors:  Itaru Endo; Mithat Gonen; Adam C Yopp; Kimberly M Dalal; Qin Zhou; David Klimstra; Michael D'Angelica; Ronald P DeMatteo; Yuman Fong; Lawrence Schwartz; Nancy Kemeny; Eileen O'Reilly; Ghassan K Abou-Alfa; Hiroshi Shimada; Leslie H Blumgart; William R Jarnagin
Journal:  Ann Surg       Date:  2008-07       Impact factor: 12.969

6.  Proposal of a new staging system for mass-forming intrahepatic cholangiocarcinoma: a multicenter analysis by the Study Group for Hepatic Surgery of the Japanese Society of Hepato-Biliary-Pancreatic Surgery.

Authors:  Takahiro Uenishi; Shunichi Ariizumi; Taku Aoki; Tomoki Ebata; Masayuki Ohtsuka; Eiichi Tanaka; Hiroshi Yoshida; Satoru Imura; Masaki Ueno; Norihiro Kokudo; Masato Nagino; Satoshi Hirano; Shoji Kubo; Michiaki Unno; Mitsuo Shimada; Hiroki Yamaue; Masakazu Yamamoto; Masaru Miyazaki; Tadahiro Takada
Journal:  J Hepatobiliary Pancreat Sci       Date:  2014-02-12       Impact factor: 7.027

7.  Regional chemotherapy for unresectable intrahepatic cholangiocarcinoma: a potential role for dynamic magnetic resonance imaging as an imaging biomarker and a survival update from two prospective clinical trials.

Authors:  Ioannis T Konstantinidis; Richard K G Do; David H Gultekin; Mithat Gönen; Lawrence H Schwartz; Yuman Fong; Peter J Allen; Michael I D'Angelica; Ronald P DeMatteo; David S Klimstra; Nancy E Kemeny; William R Jarnagin
Journal:  Ann Surg Oncol       Date:  2014-03-25       Impact factor: 5.344

8.  A phase II study of gemcitabine and cisplatin plus sorafenib in patients with advanced biliary adenocarcinomas.

Authors:  J K Lee; M Capanu; E M O'Reilly; J Ma; J F Chou; J Shia; S S Katz; B Gansukh; D Reidy-Lagunes; N H Segal; K H Yu; K-Y Chung; L B Saltz; G K Abou-Alfa
Journal:  Br J Cancer       Date:  2013-07-30       Impact factor: 7.640

9.  S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma.

Authors:  A B El-Khoueiry; C Rankin; A B Siegel; S Iqbal; I-Y Gong; K C Micetich; O R Kayaleh; H-J Lenz; C D Blanke
Journal:  Br J Cancer       Date:  2014-01-14       Impact factor: 7.640
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.